record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
accepted
frontiers / frontier
Finding bundle
back to staterecord state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding type[object Object] · [object Object] · [object Object] · [object Object] · [object Object]
evidence
source-boundexperimental · manual state transition; placebo-controlled clinical trial where source reports control arm · Homo sapiens
proof impact
packet context4 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition; placebo-controlled clinical trial where source reports control arm
evidence type
experimental
species
Homo sapiens
evidence spans
Donanemab slowed clinical decline in early symptomatic Alzheimer's disease in TRAILBLAZER-ALZ 2, with efficacy interpreted against amyloid and tau-selection criteria.
Sims et al. 2023 JAMA, TRAILBLAZER-ALZ 2 · curator_source · 10.1001/jama.2023.13239
conditions
Provenance
source title
Sims et al. 2023 JAMA, TRAILBLAZER-ALZ 2
doi
10.1001/jama.2023.13239
journal
JAMA
authors
reviewer:will-blair-bot
source record
declaredvs_1655f7a05027dbcadoi:10.1001/jama.2023.13239 · 10.1001/jama.2023.13239
inspect source →
source record
declaredvs_203b1035da52d780doi:10.1001/jama.2023.13239 · 10.1001/jama.2023.13239 · 37459141
inspect source →
source record
declaredvs_abe7b2b7a331cdf7doi:10.1001/jama.2023.13239 · 10.1001/jama.2023.13239
inspect source →
Donanemab slowed clinical decline in early symptomatic Alzheimer's disease in TRAILBLAZER-ALZ 2, with efficacy interpreted against amyloid and tau-selection criteria.
vs_abe7b2b7a331cdf7 · source:Sims et al. 2023 JAMA, TRAILBLAZER-ALZ 2|section:curator_source · manual_curation
outgoing
No outgoing links.
incoming
contradicts · vf_0767356cc73a6387
depends · vf_092bd1220b85fda6
contradicts · vf_3d75299a343a2fc8
events
vev_03ae13478d091c6dfinding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_9860367b0179abe0finding.caveatedTau-selection criteria affect generalization to broader clinical populations.
reviewer:will-blair-bot · 2026-05-06
vev_b2ed1b21631486fefinding.reviewedReviewed for decision-console use: bounded TRAILBLAZER-ALZ 2 benefit claim with trial population and biomarker-selection scope.
reviewer:will-blair-bot · 2026-05-06
vev_d7eea5ea523a177ffinding.caveatedDecision-console scope: this supports a bounded early symptomatic donanemab claim under amyloid/tau selection criteria; it does not remove the need to inspect ARIA risk, treatment discontinuation rules, and endpoint meaningfulness.
reviewer:will-blair-bot · 2026-05-06
reviewable changes
vpr_0014e47ebf928b0afinding.reviewReviewed for decision-console use: bounded TRAILBLAZER-ALZ 2 benefit claim with trial population and biomarker-selection scope.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_14efe481b72d9e44finding.caveatDecision-console scope: this supports a bounded early symptomatic donanemab claim under amyloid/tau selection criteria; it does not remove the need to inspect ARIA risk, treatment discontinuation rules, and endpoint meaningfulness.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_2ce006ffa5c100e5finding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_d9ec6f23226ebc44finding.caveatTau-selection criteria affect generalization to broader clinical populations.
applied · reviewer:will-blair-bot · 2026-05-06
evaluations
No evaluation record targets this finding id.